{"id":105,"date":"2020-10-28T12:44:10","date_gmt":"2020-10-28T12:44:10","guid":{"rendered":"https:\/\/www.embl.org\/about\/info\/mmpu\/?page_id=105"},"modified":"2026-03-26T13:01:13","modified_gmt":"2026-03-26T13:01:13","slug":"systems-medicine-of-cancer-drugs","status":"publish","type":"page","link":"https:\/\/www.embl.org\/about\/info\/mmpu\/research-groups\/systems-medicine-of-cancer-drugs\/","title":{"rendered":"Systems Medicine of Cancer Therapies"},"content":{"rendered":"\n
\n
\n\n

Group leaders: Wolfgang Huber, Sascha Dietrich and Junyan Lu<\/h2>\n\n\n\n

What motivates us<\/strong><\/h3>\n\n\n\n

Why do some cancer treatments elicit response in some patients but not others? How do cancers become resistant to treatment? These are major clinical and scientific challenges. We aim to understand the molecular biological mechanisms that underlie them. We hope to contribute to new treatment strategies, improvements to existing therapies with adjuvants or combinatorics, and better patient stratifications.<\/p>\n\n\n\n

Our approach<\/strong><\/h3>\n\n\n\n

We use a systems medicine approach that combines ex-vivo drug perturbation profiling on primary cells from lymphoma and leukaemia patients, single-cell multi-omics, and spatial omics. By machine learning \/ AI based-multi-modal integration and careful computational biology, we aim to dissect the interaction between tumour cells, the tumour microenvironment and the immune system, and modern cancer treatments such as targeted compounds and immunotherapies.<\/p>\n\n\n\n

Our joint expertise brings together:<\/p>\n\n\n\n